Autopsy report · NCT00273741

Ritalin: Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients

“difficulty of recrutement”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year before it started.
• Ran for about 2 years 5 months before it stopped.
• 39 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

University Hospital, Grenoble

Sponsor type

University, hospital or other

Conditions

Asthenia; Neoplasms

Interventions

methylphenidate; placebo comparator

Participants

39

Sites

13

Countries

France

Trials that died the same way

• ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic
  “insufficient recrutment” (67% match in meaning)
• Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes
  “Because of difficulties in recruting” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.